There are 2789 resources available
RWE: When should it be used by EMA?
Presenter: Francesco Pignatti
Session: How does real-world evidence inform decision making for new drug funding?
Resources:
Slides
Webcast
Challenges of collecting RWE: Limitations of administrative data sets, complex methodological issues, responsibility for collecting data
Presenter: Valery Lemmens
Session: How does real-world evidence inform decision making for new drug funding?
Resources:
Slides
Webcast
Introduction
Presenter: Solange Peters
Session: Beating cancer at the EU level: Influential policies changing the paradigm of the cancer (treatment) lifecycle
Resources:
Slides
ESMO’s blueprint to tackle cancer
Presenter: Rosa Giuliani
Session: Beating cancer at the EU level: Influential policies changing the paradigm of the cancer (treatment) lifecycle
Resources:
Webcast
EMA/HMA strategy 2025
Presenter: Ralf Herold
Session: Beating cancer at the EU level: Influential policies changing the paradigm of the cancer (treatment) lifecycle
Resources:
Slides
Webcast
Europe's Beating Cancer Plan
Presenter: John F. Ryan
Session: Beating cancer at the EU level: Influential policies changing the paradigm of the cancer (treatment) lifecycle
Resources:
Slides
Webcast
Pharmaceutical strategy for Europe and how to combine a thriving pharmaceutical landscape with affordable drug prices
Presenter: Ferenc Marofka
Session: Beating cancer at the EU level: Influential policies changing the paradigm of the cancer (treatment) lifecycle
Resources:
Slides
Webcast
Industry perspective
Presenter: Nathalie Moll
Session: Beating cancer at the EU level: Influential policies changing the paradigm of the cancer (treatment) lifecycle
Resources:
Webcast
Patient perspective
Presenter: Bettina Ryll
Session: Beating cancer at the EU level: Influential policies changing the paradigm of the cancer (treatment) lifecycle
Resources:
Slides
Webcast
Introduction
Presenter: Winette Van Der Graaf
Session: New standards of care in sarcomas in 2021
Resources:
Webcast